John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at Follow @JohnCFierce on Twitter.

Articles by John Carroll

Westphal's Verastem slashes staff in the wake of a clinical trial flop

Two weeks after Verastem was forced to acknowledge that its lead cancer drug had flopped badly in a clinical study for mesothelioma, founder and Executive Chairman Christoph Westphal has brought out the ax and chopped half the staff. Verastem acknowledged the move after the markets closed on Thursday, hours after word of the cuts began buzzing throughout the Boston biotech hub.

Octapharma buys into Glycotope with an €80M cash deal

Switzerland's Octapharma AG is paying €80 million to bag the exclusive worldwide license to certain IP behind Glycotope's recombinant technology as well as a minority stake in the German biotech.

Wyss spins out pathogen-capturing tech into upstart biotech

Harvard's Wyss Institute is spinning out another biotech. The cutting-edge research group has launched Opsonix with $8 million from Baxter Ventures and Hansjörg Wyss, the Swiss billionaire who founded the institute.

With FDA 'breakthrough' in hand, Eli Lilly shoots for accelerated abemaciclib OK

Eli Lilly's would-be rival to Pfizer's Ibrance (palbociclib) just gained an inside track at the FDA. Regulators handed Lilly the coveted "breakthrough therapy" designation for abemaciclib, another CDK 4/6 inhibitor with big plans for carving out a niche among patients with advanced breast cancer.

The most hated man in biotech is still confident of a comeback

He's been described as the most hated man in America. He's been kicked out of BIO, condemned by every biotech executive who's been queried by the media, lampooned on Saturday Night Live and subjected to the taunts of an online mob. But Martin Shkreli, the CEO of newborn Turing Pharmaceuticals, is still confident that he can turn it all around in his favor.

Positive PhIII leaves Neurocrine lining up for an FDA filing for tardive dyskinesia

Neurocrine Biosciences says its experimental drug for tardive dyskinesia hit the primary endpoint in a Phase III study, setting up a near-term application with the FDA and spurring a 28% spike in the biotech's share price in premarket trading.

Feeling the biotech chill, CytomX stumbles onto Nasdaq with an $80M IPO

The biotech IPO window may not be closed, but it's also not wide open--at least for now. You can add CytomX to the list of biotechs that have now stumbled their way into an IPO.

Advaxis offers a tardy defense after FDA puts cancer vaccine on hold

Two weeks after reporting that its cancer vaccine spurred a positive response among a group of cervical cancer patients in a small clinical trial, Advaxis waited until after the market closed today to reveal that the FDA has placed the same cancer vaccine--axalimogene filolisbac (ADXS-HPV)--on a clinical hold, slamming the brakes on four studies.

Rodin taps Adam Rosenberg for top post

Cambridge, MA-based Rodin Therapeutics has recruited biotech vet Adam Rosenberg as its new CEO.

Take the poll: Has the biotech boom come to an end?

Is the long-running bull market for biotech dead? Or will it rebound later this year? Take the poll.